ArticleHarm reduction journal2021
Facilitators and barriers to the regulation of medical cannabis: a scoping review of the peer-reviewed literature.
Article in Harm reduction journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Effect of CannEpilJournal of psychopharmacology (Oxford, England) · 2023Trial
- The Colombian Medical Cannabis Paradox: A Scoping Review of Structural Barriers and Health Inequity.International journal of environmental research and public health · 2025Article
- From farm to bedside: Potential of medical cannabis in global health.Complementary therapies in medicine · 2025Review
- Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects and Legal Challenges.Neurology international · 2025Review
- Healthcare Professionals' Perceptions About Medical Cannabis in Greece: A Qualitative Study.Journal of market access & health policy · 2025Article
- Assessing the Market Readiness for Medical Cannabis in Greece: A Qualitative Study of Patient Perspectives.Medicines (Basel, Switzerland) · 2025Article
- Marketing Management and Policymaking for Medical Cannabis: Overcoming Barriers and Shaping Strategies.Cannabis (Albuquerque, N.M.) · 2025Article
- School Nurse Perspectives of Medical Cannabis Policy in K-12 Schools: An Exploratory Descriptive Study.The Journal of school nursing : the official publication of the National Association of School Nurses · 2024Article
- Canada's Recreational Cannabis Legalization and Medical Cannabis Patient Activity, 2017-2022.American journal of public health · 2024Article
- A semi-naturalistic open-label study examining the effect of prescribed medical cannabis use on simulated driving performance.Journal of psychopharmacology (Oxford, England) · 2024Article
- Nanocarriers for Cannabinoid Delivery: Enhancing Therapeutic Potential.Recent advances in drug delivery and formulation · 2024Review
- Effects of U.S. State Medical Cannabis Laws on Treatment of Chronic Noncancer Pain.Annals of internal medicine · 2023Article
- The quality of health information provided on web sites selling cannabis to consumers in Canada is poor.Harm reduction journal · 2022Article
- Exploration of facilitators and barriers to the regulatory frameworks of dietary and herbal supplements: a scoping review.Journal of pharmaceutical policy and practice · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent decades, several political, legislative, judicial, consumer, and commercial processes around the world have advanced legalization efforts for the use of medical cannabis (MC). As the use of MC evolves through legislative reform, with an increase in public acceptance and therapeutic potential, a need exists to further investigate the facilitators and barriers to MC regulation.
methodsA scoping review was conducted to identify the facilitators and barriers associated with the implementation of MC regulations. MEDLINE, EMBASE, AMED and PsycINFO databases were systematically searched; no restrictions were placed on geographic location/jurisdiction. Eligible articles included those that evaluated the MC regulatory framework of one or more countries.
resultsTwenty-two articles were deemed eligible and included in this review. Themes identified include: (1) effects of conflicts, mindset, and ideology of state population, (2) the use of comparisons to analyze MC regulation, and (3) the need for more knowledge, advice, and empirical/clinical evidence to inform future MC policies.
conclusionPolicymakers should be aware of facilitators to the MC regulation implementation process, such as the influence of state and federal congruence, increased transparency, and the incorporation of stakeholder concerns, in order to effectively respond to a growing societal acceptance of MC and its use among patients. Given a comprehensive understanding of these influential factors, policymakers may be better equipped to meet the consumer and commercial demands of a rapidly evolving MC regulatory environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.